IDEXX Laboratories falls after BofA cuts PT on vet visit trends
View all comments(0)
Animal diagnostics maker IDEXX Laboratories' IDXX.O shares down 1.2% at $406.41
BofA Global Research cuts PT to $475 from $535 on vet visit declines
The new PT represents a 30% upside to the stock's last close
"IDXX's direct leverage to clinic visit volumes creates a tough setup given the weak readings through Q1 and April so far" - BofA
Brokerage says vet visit trends "leave a little room for upside revisions"
IDXX expects about a 2% decline in clinical visits for 2025 - co said on a Q4 conference call
Eight of 14 brokerages rate the stock "buy" or higher, six "hold"; their median PT is $502.13 - LSEG
Including session's move, IDXX down 1.5% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.